{
    "clinical_study": {
        "@rank": "104291", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Experimental", 
                "description": "Dabrafenib/Trametinib/MEDI4736"
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Experimental", 
                "description": "Trametinib/MEDI4736"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Experimental", 
                "description": "Trametinib/MEDI4736"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the maximum tolerated dose and the safety profile\n      of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone in\n      subjects with metastatic or unresectable melanoma with BRAF-mutation positive or Wild Type\n      BRAF, respectively."
        }, 
        "brief_title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults >/= 18 years old\n\n          -  Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable)\n             or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive\n             (cohort A) or mutation-negative (cohorts B and C)\n\n          -  ECOG performance status of 0 or 1\n\n          -  Measurable disease by radiographic or physical examination\n\n          -  Adequate organ and marrow function\n\n          -  Willingness to provide consent for biopsies positive or BRAF WT measurable disease,\n             Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate\n             organ and marrow function\n\n        Exclusion Criteria:\n\n          -  Prior treatment with a BRAF inhibitor or MEK inhibitor\n\n          -  Any prior Grade \u2265 3 immune-related adverse event while receiving immunotherapy\n\n          -  Active or prior documented autoimmune disease within the past 2 years\n\n          -  History of or current risk for retinal vein occlusion (RVO) or central serous\n             retinopathy (CSR)\n\n          -  History of or current cardiovascular risk including myocardial infarction, \u2265 Class II\n             congestive heart failure,  uncontrolled arrhythmias, or refractory hypertension\n\n          -  Active, untreated CNS metastases\n\n          -  Women who are pregnant or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027961", 
            "org_study_id": "CD-ON-MEDI4736-1161"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C"
                ], 
                "description": "MEDI4736", 
                "intervention_name": "MEDI4736", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort A", 
                "description": "Dabrafenib", 
                "intervention_name": "Dabrafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C"
                ], 
                "description": "Trametinib", 
                "intervention_name": "Trametinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Metastatic or Unresectable Melanoma, MEDI4736, dafrafenib, trametinib, BRAF-mutation positive, wild-type BRAF, PD-L1, PD-1", 
        "lastchanged_date": "April 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone", 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "Shaista Parveen"
        }, 
        "overall_contact_backup": {
            "email": "clinicaltrialenquiries@medimmune.com", 
            "last_name": "Sherry Warwick"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Andy Blake-Haskins, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint for determining maximum tolerated dose includes dose limiting toxicities. The primary endpoint for safety assessment include adverse events, serious adverse events, laboratory evaluations, vitial signs, physical examination, and echocardiogram/elecrocardiogram results.", 
            "measure": "Maximum Tolerated Dose/Safety", 
            "safety_issue": "Yes", 
            "time_frame": "90 days after the last dose of MEDI4736"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The endpoints for assessment of antitumor activity include objective response based on revised RECIST criteria Version 1.1, duration of response, progression-free survival, and overall survival.", 
                "measure": "Antitumor Activity", 
                "safety_issue": "No", 
                "time_frame": "90 days after the last dose of investigational product"
            }, 
            {
                "description": "The endpoints for assessment of antitumor activity include disease control, based on revised RECIST criteria Version 1.1, duration of response, progression-free survival, and overall survival.", 
                "measure": "Antitumor Activity", 
                "safety_issue": "No", 
                "time_frame": "90 days after the last dose of investigational product"
            }, 
            {
                "description": "PK of MEDI4736 includes individual MEDI4736 concentrations in serum.", 
                "measure": "Pharmacokinetic of MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "PK parameters of MEDI4736 including peak concentration, area under the concentration-time curve clearance and half-life.", 
                "measure": "Pharmacokinetic of MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "Immunogenicity of MEDI4736 include the number and percentage of subjects who develop detectable anti-drug antibodies.", 
                "measure": "Immunogenicity of MEDI4736", 
                "safety_issue": "Yes", 
                "time_frame": "90 days after the last dose of MEDI4736"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}